title: Proposition 71 and CIRM--assessing the return on investment.
abstract: Given that Californian voters authorized state coffers to sell $3 billion in bonds to fund the California Institute for Regenerative Medicine (CIRM) with the expectation of health and financial benefits, what benchmarks should be used to measure the initiative's success?
authors.affiliation: Department of Surgery, Institute of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, 257 Campus Drive West, Stanford, California 94305, USA. longaker@stanford.edu
authors.forename: Michael T
authors.initials: MT
authors.lastname: Longaker
authors.forename: Laurence C
authors.initials: LC
authors.lastname: Baker
authors.forename: Henry T
authors.initials: HT
authors.lastname: Greely
mesh_terms: D000047:Academies and Institutes / Q000191:economics* / Q000331:legislation & jurisprudence*; D019985:Benchmarking / Q000379:methods; D035843:Biomedical Research / Q000191:economics / Q000331:legislation & jurisprudence; D002140:California; D003362:Cost-Benefit Analysis; D033041:Embryo Research / Q000191:economics* / Q000331:legislation & jurisprudence*; D044968:Regenerative Medicine / Q000191:economics* / Q000331:legislation & jurisprudence*; D013219:State Government